Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Matthew G Cyr"'
Autor:
Christoph Rader, Adrian Wiestner, Jing Chang, Matthew G Cyr, Maissa Mhibik, Junpeng Qi, Haiyong Peng, Erika M Gaglione, David Eik, John Herrick, Thomas Venables, Scott J Novick, Valentine V Courouble, Patrick R Griffin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 11 (2022)
Background Despite numerous therapeutic options, safe and curative therapy is unavailable for most patients with chronic lymphocytic leukemia (CLL). A drawback of current therapies such as the anti-CD20 monoclonal antibody (mAb) rituximab is the elim
Externí odkaz:
https://doaj.org/article/540fafe660a248c8baf6af7c92d6611f
Autor:
Jessica Nunes, Rakeb Tafesse, Charlene Mao, Matthew Purcell, Xiaokui Mo, Liwen Zhang, Meixiao Long, Matthew G. Cyr, Christoph Rader, Natarajan Muthusamy
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-20 (2024)
Abstract Siglec-6 is a lectin receptor with restricted expression in the placenta, mast cells and memory B-cells. Although Siglec-6 is expressed in patients with chronic lymphocytic leukemia (CLL), its pathophysiological role has not been elucidated.
Externí odkaz:
https://doaj.org/article/77c2a2030f1740c4a3efc4a6ce473897
Autor:
Matthew G Cyr, Maissa Mhibik, Junpeng Qi, Haiyong Peng, Jing Chang, Erika M Gaglione, David Eik, John Herrick, Thomas Venables, Scott J Novick, Valentine V Courouble, Patrick R Griffin, Adrian Wiestner, Christoph Rader
Publikováno v:
Journal for immunotherapy of cancer. 10(11)
BackgroundDespite numerous therapeutic options, safe and curative therapy is unavailable for most patients with chronic lymphocytic leukemia (CLL). A drawback of current therapies such as the anti-CD20 monoclonal antibody (mAb) rituximab is the elimi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41cb0d3beeb9682855f3e016b6183391
https://pubmed.ncbi.nlm.nih.gov/36442911
https://pubmed.ncbi.nlm.nih.gov/36442911
Autor:
Matthew G. Cyr, Henry D. Wilson, Anna-Lena Spierling, Jing Chang, Haiyong Peng, Peter Steinberger, Christoph Rader
Publikováno v:
Journal of Molecular Biology. 435:168085
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac4b21e06c55b2f934ff6eaa13d747fc
https://doi.org/10.1016/j.jmb.2023.168085
https://doi.org/10.1016/j.jmb.2023.168085
Autor:
Elisaveta Voynova, Stefania Pittaluga, Samantha Simon, Damian Kovalovsky, Adrian Wiestner, Matthew G. Cyr, Jeong Heon Yoon, Christoph Rader, Julie Alejo, Ronald E. Gress
Publikováno v:
Leukemia
The only current curative treatment for chronic lymphocytic leukemia (CLL) is allogenic hematopoietic stem cell transplantation. Chimeric antigen receptor treatment targeting CD19 for CLL achieved some complete responses, suggesting the need for alte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d70e6ffa25f954d1d8ff7d3b635c8f2b
https://pubmed.ncbi.nlm.nih.gov/33633313
https://pubmed.ncbi.nlm.nih.gov/33633313
Autor:
Ina C. Wecken, Adrian Wiestner, Jo Soden, Jim Freeth, Brian C. Shaffer, Jing Chang, Christoph Rader, Sivasubramanian Baskar, Gustavo J. Martinez, Haiyong Peng, Matthew G. Cyr
Publikováno v:
Cancer Immunology Research. 6:1008-1013
Although the 5-year survival rate of chronic lymphocytic leukemia (CLL) patients has risen to >80%, the only potentially curative treatment is allogeneic hematopoietic stem cell transplantation (alloHSCT). To identify possible new monoclonal antibody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a34bb53b673c0977b21bf95c52cd131
https://doi.org/10.1158/2326-6066.cir-18-0102
https://doi.org/10.1158/2326-6066.cir-18-0102
Autor:
Matthew D. Hall, Stephen C. Kales, John R. Shanks, Clayton B. Woodcock, Katherine Pohida, Ganesha Rai, Xin Xu, Xiaodong Cheng, Qin Chen, Bryan T. Mott, Xing Zhang, Daniel J. Jansen, David J. Maloney, Ajit Jadhav, Matthew G. Cyr, Xin Hu, Pranav Shah, John R. Horton, Xu Liu, Haian Fu, Paula M. Vertino, Mark J. Henderson, Anton Simeonov
The active sites of hundreds of human α-ketoglutarate (αKG) and Fe(II)-dependent dioxygenases are exceedingly well preserved, which challenges the design of selective inhibitors. We identified a noncatalytic cysteine (Cys481 in KDM5A) near the acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1a9df54129d98fb0b1a05fc30b2f7bc
https://europepmc.org/articles/PMC6467790/
https://europepmc.org/articles/PMC6467790/
A widely-applicable high-throughput cellular thermal shift assay (CETSA) using split Nano Luciferase
Autor:
Ganesha Rai, Alexey V. Zakharov, Eric Wallgren, Natalia J. Martinez, Jacob S. Roth, Daniel J. Urban, Rosita R. Asawa, Matthew D. Hall, Juan J. Marugan, Anton Simeonov, Shyh-Ming Yang, Carleen Klumpp-Thomas, Mark J. Henderson, Matthew G. Cyr, Nathan P. Coussens
Publikováno v:
Scientific Reports
Scientific Reports, Vol 8, Iss 1, Pp 1-16 (2018)
Scientific Reports, Vol 8, Iss 1, Pp 1-16 (2018)
Assessment of the interactions between a drug and its protein target in a physiologically relevant cellular environment constitutes a major challenge in the pre-clinical drug discovery space. The Cellular Thermal Shift Assay (CETSA) enables such an a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17b3f9e7a1f40dd524617adb91387d57
http://europepmc.org/articles/PMC6013488
http://europepmc.org/articles/PMC6013488